4//SEC Filing
Van Strydonck, Gerald E. 4
Accession 0000891839-20-000018
CIK 0001205922other
Filed
Jan 5, 7:00 PM ET
Accepted
Jan 6, 4:34 PM ET
Size
13.8 KB
Accession
0000891839-20-000018
Insider Transaction Report
Form 4
VACCINEX, INC.VCNX
Van Strydonck, Gerald E.
Director
Transactions
- Award
Stock Option (Right to Buy)
2019-12-31+2,737→ 2,737 totalExercise: $4.85From: 2019-12-31Exp: 2029-12-28→ Common Stock (2,737 underlying)
Holdings
- 7,500
Stock Option (Right to Buy)
Exercise: $14.90Exp: 2023-03-06→ Common Stock (7,500 underlying) - 4,500
Stock Option (Right to Buy)
Exercise: $10.00Exp: 2020-03-06→ Common Stock (4,500 underlying) - 6,396
Stock Option (Right to Buy)
Exercise: $13.60Exp: 2027-09-15→ Common Stock (6,396 underlying) - 7,718
Stock Option (Right to Buy)
Exercise: $7.78From: 2020-05-15→ Common Stock (7,718 underlying) - 1,856
Stock Option (Right to Buy)
Exercise: $7.17From: 2019-09-30Exp: 2029-09-27→ Common Stock (1,856 underlying) - 2,501
Stock Option (Right to Buy)
Exercise: $5.26Exp: 2029-03-30→ Common Stock (2,501 underlying)
Footnotes (3)
- [F1]Exercisable in full as of the date of this report.
- [F2]This option was granted pursuant to the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and expires on May 14, 2029 or five years following retirement or cessation of services, whichever occurs first.
- [F3]Pursuant to the Issuer's Director Compensation Program, in a transaction exempt under Rule 16b-3, the reporting person elected to receive these options in lieu of $8,750 for retainer and meeting fees during the fourth quarter of 2019. The number of options was calculated in accordance with the Black-Scholes valuation model and all such options are immediately exercisable.
Documents
Issuer
VACCINEX, INC.
CIK 0001205922
Entity typeother
Related Parties
1- filerCIK 0001748247
Filing Metadata
- Form type
- 4
- Filed
- Jan 5, 7:00 PM ET
- Accepted
- Jan 6, 4:34 PM ET
- Size
- 13.8 KB